Lachica, Adela .

HRN: 23-15-65  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/14/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
06/14/2023
06/21/2023
IVT
600mg
Q6
Abscess, Lumbar Area, Right Cannot Totally Rule Out Cellulitis
Waiting Final Action 
06/14/2023
OXACILLIN 500MG (VIAL)
06/14/2023
06/21/2023
IVT
1.5gms
Q6
Abscess, Lumbar Area, Right Cannot Totally Rule Out Cellulitis
Waiting Final Action 
06/14/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
06/14/2023
06/21/2023
IV
4.5g
Q8
Cellulitis
Waiting Final Action 
06/14/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
06/14/2023
06/21/2023
IV
4.5g
Q8
Cellulitis
Waiting Final Action 
06/14/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
06/14/2023
06/21/2023
IV
4.5g
Q8
Cellulitis
Waiting Final Action 
06/22/2023
CLINDAMYCIN 300MG (CAP)
06/22/2023
06/29/2023
PO
300mg
Q8hrs
Lumbar Abscess
Waiting Final Action 
06/22/2023
FLUCONAZOLE 50MG (CAP)
06/22/2023
07/06/2023
PO
200mg
Once Daily
Empiric
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: